News headlines about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a news impact score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.7813662313817 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

NASDAQ:BCLI traded down $0.08 during trading hours on Friday, reaching $3.92. The company had a trading volume of 24,776 shares, compared to its average volume of 41,603. Brainstorm Cell Therapeutics has a 52 week low of $2.88 and a 52 week high of $5.35. The company has a market cap of $82.68 million, a PE ratio of -15.08 and a beta of 2.06.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Monday, July 23rd. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). equities analysts predict that Brainstorm Cell Therapeutics will post -0.49 earnings per share for the current year.

A number of equities research analysts have commented on the stock. Maxim Group set a $9.00 target price on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Monday, July 23rd. HC Wainwright set a $11.00 target price on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, May 29th. Finally, ValuEngine raised shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, May 16th.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Featured Story: Using the New Google Finance Tool

Insider Buying and Selling by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with's FREE daily email newsletter.